

UNITED STATES PARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED	INVENTOR		ATTORNEY DOCKET NO.
09/684,061	10/06/00	BARTELMEZ		s	0450-0031.30
Г		HM12/0427	コ		EXAMINER
IOTA PI LAW	MP1127-0427		ZARA, J		
P O BOX 608	50			ART UNIT	PAPER NUMBER
PALO ALTO C	A 94306-085	0		1635 DATE MAILED:	04/27/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

		Application No.	Applicant(s)					
Office Action Summary		09/684,061	BARTELMEZ ET AL.					
		Examiner	Art Unit					
		Jane Zara	1635					
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status								
1) 🗌 🛚 🖡	Responsive to communication(s) filed on	•						
2a)□ ¯	This action is FINAL . 2b) ☐ TI	nis action is non-final.						
3) 🗌 🥫	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.								
6)□ C	6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.								
8) Claims 1-20 are subject to restriction and/or election requirement.								
Application Papers								
9)□ T	he specification is objected to by the Examir	ner.						
10) ☐ The drawing(s) filed on is/are objected to by the Examiner.								
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved.								
12) The oath or declaration is objected to by the Examiner.								
Priority un	der 35 U.S.C. § 119		•					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
1. Certified copies of the priority documents have been received.								
2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).								
Attachment(s)								
	e of References Cited (PTO-892)	18) Interview Summ	ary (PTO-413) Paper No(s)					
16) Notice	e of References Cited (F10-032) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s	19) Notice of Inform	al Patent Application (PTO-152)					

File

Application/Control Number: 09/684,061

Art Unit: 1635

Page 2

DETAILED ACTION

Claims 1-20 are pending in the instant application.

Election/Restriction

Claims 2, 6, 11 and 15 are drawn to nucleotide sequences, nucleotide constructs, and/or methods requiring the use of nucleotide sequences or nucleotide constructs that contain more than one individual, independent, and distinct nucleotide sequence in alternative form.

Accordingly, these claims are subject to restriction under 35 U.S.C. § 121 as outlined in 1192 O.G. 68 (Nov. 19, 1996).

Applicant is required to select **no more than one of the individual sequences** for examination. The search of no more than one selected sequence may include the complements of the selected sequence and, where appropriate, may include subsequences within the selected sequence (e.g., oligomeric probes and/or primers).

Applicants should note that the claims which were found to be generic to the individual sequences or target genes will be examined according to the limitations of the elected sequence or elected target gene.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/684,061 Page 3

Art Unit: 1635

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Application/Control Number: 09/684,061

Art Unit: 1635

Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone numbers for the Group are (703) 308-4242 and (703) 305-3014. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (703) 306-5820. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (703) 308-0447. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (703) 305-3413. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JZ

April 23, 2001

ENT EXAMINER

Page 4

TC1600